Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe
Adjunctive BRV was effective in clinical practice in patients with predominantly difficult-to-treat FOS, as shown by BRV retention rate of 57.7% at 12 months, which is in line with real-world retention rates for other new-generation ASMs.
Authors
- Colin P. Doherty (ORCID: https://orcid.org/0000-0002-8869-8567)
- Anne‐Liv Schulz
- Eduardo Rubio-Nazábal (ORCID: https://orcid.org/0000-0003-3049-987X)
- Jakob Christensen (ORCID: https://orcid.org/0000-0002-9385-6435)
- Anna Kelemen (ORCID: https://orcid.org/0000-0003-0531-9830)
- F Brock
- Bernhard J. Steinhoff (ORCID: https://orcid.org/0000-0001-5995-5862)
- Iryna Leunikava
- Dimitrios Bourikas (ORCID: https://orcid.org/0009-0005-4503-0734)
- Marian Majoie (ORCID: https://orcid.org/0000-0003-0579-8122)
Institutions
- Universidade da Coruña (ES)
- Royal College of Surgeons in Ireland (IE)
- University of Freiburg (DE)
- Trinity College (CA)
- Trinity College Dublin (IE)
- Aarhus University Hospital (DK)
- Maastricht University (NL)
- Bernstein Center for Computational Neuroscience Freiburg (DE)
- Kempenhaeghe (NL)
- Diakonie Kork (DE)
- UCB Pharma (Germany) (DE)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s40120-024-00697-4
- Citations
- 5
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.36
Funders
- UCB